236 related articles for article (PubMed ID: 16243825)
1. In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor.
van der Heijden MS; Brody JR; Dezentje DA; Gallmeier E; Cunningham SC; Swartz MJ; DeMarzo AM; Offerhaus GJ; Isacoff WH; Hruban RH; Kern SE
Clin Cancer Res; 2005 Oct; 11(20):7508-15. PubMed ID: 16243825
[TBL] [Abstract][Full Text] [Related]
2. Functional defects in the fanconi anemia pathway in pancreatic cancer cells.
van der Heijden MS; Brody JR; Gallmeier E; Cunningham SC; Dezentje DA; Shen D; Hruban RH; Kern SE
Am J Pathol; 2004 Aug; 165(2):651-7. PubMed ID: 15277238
[TBL] [Abstract][Full Text] [Related]
3. Targeted disruption of FANCC and FANCG in human cancer provides a preclinical model for specific therapeutic options.
Gallmeier E; Calhoun ES; Rago C; Brody JR; Cunningham SC; Hucl T; Gorospe M; Kohli M; Lengauer C; Kern SE
Gastroenterology; 2006 Jun; 130(7):2145-54. PubMed ID: 16762635
[TBL] [Abstract][Full Text] [Related]
4. Direct interaction of the Fanconi anaemia protein FANCG with BRCA2/FANCD1.
Hussain S; Witt E; Huber PA; Medhurst AL; Ashworth A; Mathew CG
Hum Mol Genet; 2003 Oct; 12(19):2503-10. PubMed ID: 12915460
[TBL] [Abstract][Full Text] [Related]
5. Fanconi anemia FANCG protein in mitigating radiation- and enzyme-induced DNA double-strand breaks by homologous recombination in vertebrate cells.
Yamamoto K; Ishiai M; Matsushita N; Arakawa H; Lamerdin JE; Buerstedde JM; Tanimoto M; Harada M; Thompson LH; Takata M
Mol Cell Biol; 2003 Aug; 23(15):5421-30. PubMed ID: 12861027
[TBL] [Abstract][Full Text] [Related]
6. Gene-specific selection against experimental fanconi anemia gene inactivation in human cancer.
Gallmeier E; Hucl T; Calhoun ES; Cunningham SC; Bunz F; Brody JR; Kern SE
Cancer Biol Ther; 2007 May; 6(5):654-60. PubMed ID: 17387268
[TBL] [Abstract][Full Text] [Related]
7. Fanconi anemia pathway-deficient tumor cells are hypersensitive to inhibition of ataxia telangiectasia mutated.
Kennedy RD; Chen CC; Stuckert P; Archila EM; De la Vega MA; Moreau LA; Shimamura A; D'Andrea AD
J Clin Invest; 2007 May; 117(5):1440-9. PubMed ID: 17431503
[TBL] [Abstract][Full Text] [Related]
8. Fanconi anemia pathway heterogeneity revealed by cisplatin and oxaliplatin treatments.
Kachnic LA; Li L; Fournier L; Willers H
Cancer Lett; 2010 Jun; 292(1):73-9. PubMed ID: 20034732
[TBL] [Abstract][Full Text] [Related]
9. The Fanconi anemia complementation group C gene product: structural evidence of multifunctionality.
Pang Q; Christianson TA; Keeble W; Diaz J; Faulkner GR; Reifsteck C; Olson S; Bagby GC
Blood; 2001 Sep; 98(5):1392-401. PubMed ID: 11520787
[TBL] [Abstract][Full Text] [Related]
10. Germ line Fanconi anemia complementation group C mutations and pancreatic cancer.
Couch FJ; Johnson MR; Rabe K; Boardman L; McWilliams R; de Andrade M; Petersen G
Cancer Res; 2005 Jan; 65(2):383-6. PubMed ID: 15695377
[TBL] [Abstract][Full Text] [Related]
11. Fanconi anemia gene mutations in young-onset pancreatic cancer.
van der Heijden MS; Yeo CJ; Hruban RH; Kern SE
Cancer Res; 2003 May; 63(10):2585-8. PubMed ID: 12750283
[TBL] [Abstract][Full Text] [Related]
12. Experimental study of combination therapy with S-1 against pancreatic cancer.
Yoshizawa J; Takizawa A; Takeuchi O; Hiraku O; Sasaki K; Morimoto Y; Atsuda K; Inoue G; Suzuki Y; Asanuma F; Yamada Y
Cancer Chemother Pharmacol; 2009 Nov; 64(6):1211-9. PubMed ID: 19337733
[TBL] [Abstract][Full Text] [Related]
13. Cellular characterization of cells from the Fanconi anemia complementation group, FA-D1/BRCA2.
Godthelp BC; van Buul PP; Jaspers NG; Elghalbzouri-Maghrani E; van Duijn-Goedhart A; Arwert F; Joenje H; Zdzienicka MZ
Mutat Res; 2006 Oct; 601(1-2):191-201. PubMed ID: 16920162
[TBL] [Abstract][Full Text] [Related]
14. Resistance to mitomycin C requires direct interaction between the Fanconi anemia proteins FANCA and FANCG in the nucleus through an arginine-rich domain.
Kruyt FA; Abou-Zahr F; Mok H; Youssoufian H
J Biol Chem; 1999 Nov; 274(48):34212-8. PubMed ID: 10567393
[TBL] [Abstract][Full Text] [Related]
15. Acquired FANCA dysfunction and cytogenetic instability in adult acute myelogenous leukemia.
Lensch MW; Tischkowitz M; Christianson TA; Reifsteck CA; Speckhart SA; Jakobs PM; O'Dwyer ME; Olson SB; Le Beau MM; Hodgson SV; Mathew CG; Larson RA; Bagby GC
Blood; 2003 Jul; 102(1):7-16. PubMed ID: 12637330
[TBL] [Abstract][Full Text] [Related]
16. Genetic inactivation of the Fanconi anemia gene FANCC identified in the hepatocellular carcinoma cell line HuH-7 confers sensitivity towards DNA-interstrand crosslinking agents.
Palagyi A; Neveling K; Plinninger U; Ziesch A; Targosz BS; Denk GU; Ochs S; Rizzani A; Meier D; Thasler WE; Hanenberg H; De Toni EN; Bassermann F; Schäfer C; Göke B; Schindler D; Gallmeier E
Mol Cancer; 2010 May; 9():127. PubMed ID: 20509860
[TBL] [Abstract][Full Text] [Related]
17. Fanconi anemia genes act to suppress a cross-linker-inducible p53-independent apoptosis pathway in lymphoblastoid cell lines.
Kruyt FA; Dijkmans LM; van den Berg TK; Joenje H
Blood; 1996 Feb; 87(3):938-48. PubMed ID: 8562965
[TBL] [Abstract][Full Text] [Related]
18. BIK (NBK) is a mediator of the sensitivity of Fanconi anaemia group C lymphoblastoid cell lines to interstrand DNA cross-linking agents.
Prieto-Remón I; Sánchez-Carrera D; López-Duarte M; Richard C; Pipaón C
Biochem J; 2012 Nov; 448(1):153-63. PubMed ID: 22873408
[TBL] [Abstract][Full Text] [Related]
19. The genetics of FANCC and FANCG in familial pancreatic cancer.
Rogers CD; van der Heijden MS; Brune K; Yeo CJ; Hruban RH; Kern SE; Goggins M
Cancer Biol Ther; 2004 Feb; 3(2):167-9. PubMed ID: 14726700
[TBL] [Abstract][Full Text] [Related]
20. Fanconi anemia proteins localize to chromatin and the nuclear matrix in a DNA damage- and cell cycle-regulated manner.
Qiao F; Moss A; Kupfer GM
J Biol Chem; 2001 Jun; 276(26):23391-6. PubMed ID: 11297559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
